AFLIBERCEPT IS A VEGF-TRAP MOLECULE BUILT FROM NATIVE RECEPTOR DOMAINS

^[1][2]

Aflibercept is a fusion protein built from portions of the native human receptors VEGFR-1 and VEGFR-2. It acts as a decoy receptor for VEGF-A, VEGF-B, PlGF and Gal-1.^[1][2][3]

Aflibercept molecule

The rationale for testing a high molar dose

This is a purely illustrative hypothesis for duration of effect of a higher molar dose vs a lower molar dose. Preclinical and clinical testing of an agent must be conducted to determine the safety, efficacy and durability profiles.

Model of logarithmic intraocular drug concentration over time^[4][5]*

Adapted from Schubert W, et al. 2022 & EPAR report. 2024.

*The impact of molecular properties on clinical outcomes is yet to be defined. This is a hypothetical, illustrative model based on in vitro data.

Expert opinion on high molar dose with EYLEA 8 mg

Michael Stewart, Professor of Ophthalmology Research (Mayo Clinic, Florida), talks about the rationale behind the high molar dose and pharmacokinetics of EYLEA 8 mg.

Prescribing information for EYLEA® (aflibercept) can be found here.

Abbreviations

DMO, diabetic macular oedema. Fc, fragment crystallisable. Gal-1, galectin-1. IgG, immunoglobulin G. nAMD, neovascular (wet) age-related macular degeneration. PK, pharmacokinetic. PIGF, placental growth factor. VEGF, vascular endothelial growth factor. VEGFR, vascular endothelial growth factor receptor.